Celltrion is going to launch a global targeting of Regkirona (Regdanvimab), COVID-19 antibody treatment drug developed with its own technology. The government plans to eliminate controversy over efficacy and revitalize domestic and foreign markets through large-scale clinical trials.

Celltrion held an online press conference on the morning of the 14th to introduce the results of clinical trials in Regkirona.

Regkirona is a COVID-19 antibody drug developed by Celltrion. Based on the results of clinical trial in February, it has been supplied to medical institutions with conditional permission from the MFDS. Among patients confirmed with COVID-19, symptoms develop within seven days and do n